Cargando…

COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…

Detalles Bibliográficos
Autor principal: Erol, Çetin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Cardiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682601/
https://www.ncbi.nlm.nih.gov/pubmed/36317520
http://dx.doi.org/10.5152/AnatolJCardiol.2022.11
_version_ 1784834884874797056
author Erol, Çetin
author_facet Erol, Çetin
author_sort Erol, Çetin
collection PubMed
description
format Online
Article
Text
id pubmed-9682601
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Turkish Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-96826012022-11-29 COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors… Erol, Çetin Anatol J Cardiol Editorial Turkish Society of Cardiology 2022-11-01 /pmc/articles/PMC9682601/ /pubmed/36317520 http://dx.doi.org/10.5152/AnatolJCardiol.2022.11 Text en © Copyright 2022 authors https://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Editorial
Erol, Çetin
COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
title COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
title_full COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
title_fullStr COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
title_full_unstemmed COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
title_short COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
title_sort cop27 climate change conference editorial, tavi, sglt2 inhibitors…
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682601/
https://www.ncbi.nlm.nih.gov/pubmed/36317520
http://dx.doi.org/10.5152/AnatolJCardiol.2022.11
work_keys_str_mv AT erolcetin cop27climatechangeconferenceeditorialtavisglt2inhibitors